{"product_id":"dbvt-vrio-analysis","title":"DBV Technologies S.A. (DBVT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to sustained success for DBV Technologies S.A. (DBVT) requires a deep dive into its very foundation; this VRIO Analysis rigorously tests whether its current resources possess the necessary Value, Rarity, Inimitability, and Organization to secure a lasting competitive edge. Dive in below to see the distilled verdict on what truly sets this business apart and where its future strength lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 1. Proprietary Viaskin® Technology Platform (EPIT)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of DBV Technologies S.A., the Proprietary Viaskin® Technology Platform, or EPIT. Honestly, this is where the entire investment thesis rests. It’s a novel, non-invasive way to treat food allergies by delivering microgram amounts of allergen through the skin to teach the immune system tolerance. That addresses a massive, painful unmet medical need in the market.\u003c\/p\u003e\n\u003cp\u003eThe commitment to this platform is clear in their 2025 spending. For the nine months ending September 30, 2025, operating expenses hit \u003cstrong\u003e$107.0 million\u003c\/strong\u003e, all aimed at moving this technology forward. Plus, they secured significant capital to see it through, announcing a financing of up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e in March 2025 to fund the BLA preparation and potential U.S. launch.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the current operational focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCOMFORT Toddlers study enrolling approximately \u003cstrong\u003e480 subjects\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVITESSE trial completed final patient visit (\u003cstrong\u003e654 children\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eBLA submission anticipated for toddlers in \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash position as of September 30, 2025, was \u003cstrong\u003e$69.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the regulatory uncertainty that has dogged the stock, but the current path seems more defined. If onboarding takes 14+ days, churn risk rises, but they are focused on execution now.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s competitive standing, based on the VRIO framework, looks strong because the technology itself is the moat.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNon-invasive treatment for massive unmet need; previous data showed \u003cstrong\u003e81%\u003c\/strong\u003e tolerance in toddlers after two years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eSpecific application maturity in epicutaneous immunotherapy is rare among clinical-stage biotechs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eProtected by patents; know-how for manufacturing and clinical scale-up is difficult to replicate quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eCompany focus is entirely on leveraging EPIT for food allergies, with BLA prep underway.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe foundational, patented technology creates a significant barrier to entry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe structure is there to capitalize on this asset. The organization is clearly aligned to push the Viaskin Peanut patch through the final hurdles. To be fair, the market is waiting on the VITESSE topline results, expected in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e, which will be the next major catalyst to confirm this sustained advantage.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 2. Viaskin® Peanut Clinical Data Package\n\u003c\/h2\u003e\n\u003cp\u003eThe Viaskin® Peanut clinical data package represents the most advanced, near-term commercial opportunity for DBV Technologies.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis asset is closest to commercialization, with VITESSE Phase 3 results expected in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e and a planned Biologics License Application (BLA) submission for the 4-7 age group in \u003cstrong\u003eH1 2026\u003c\/strong\u003e. This is their near-term revenue driver. The BLA submission timeline was accelerated by approximately \u003cstrong\u003eone year\u003c\/strong\u003e due to the FDA agreement that safety data from VITESSE and OLE studies are sufficient, rendering the COMFORT Children study unnecessary. The VITESSE Phase 3 trial is a 12-month study evaluating efficacy and safety in \u003cstrong\u003e654 subjects\u003c\/strong\u003e across \u003cstrong\u003e86 sites\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate. Other companies are in the allergy space, but a late-stage, near-BLA asset for peanut allergy is rare. Prior Phase III PEPITES trial showed a statistically significant response: \u003cstrong\u003e35.3%\u003c\/strong\u003e of patients responded to Viaskin Peanut 250 µg versus \u003cstrong\u003e13.6%\u003c\/strong\u003e in the placebo arm (difference = \u003cstrong\u003e21.7%\u003c\/strong\u003e; p=\u003cstrong\u003e0.00001\u003c\/strong\u003e). The mean Cumulative Reactive Dose (CRD) increased to approximately \u003cstrong\u003e900 mg\u003c\/strong\u003e of peanut protein after 12 months of treatment, compared to \u003cstrong\u003e360 mg\u003c\/strong\u003e in the placebo arm. For context, one peanut contains approximately \u003cstrong\u003e250 mg\u003c\/strong\u003e of peanut protein.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. Once approved, competitors will race to imitate the clinical profile, but the first-mover advantage is key. Data from the EPITOPE Phase 3 Open-Label Extension (OLE) study for toddlers (1-3 years) suggests sustained benefit: after \u003cstrong\u003e36 months\u003c\/strong\u003e, \u003cstrong\u003e83.5%\u003c\/strong\u003e of participants on Viaskin Peanut 250 µg reached an Eliciting Dose (ED) of $\\geq$\u003cstrong\u003e1,000 mg\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eHigh. The entire \u003cstrong\u003e2025\u003c\/strong\u003e financing was explicitly aimed at advancing this BLA and U.S. launch prep. DBV announced financing of up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e (€\u003cstrong\u003e284.5 million\u003c\/strong\u003e) in March 2025, with upfront gross proceeds of \u003cstrong\u003e$125.5 million\u003c\/strong\u003e (€\u003cstrong\u003e116.3 million\u003c\/strong\u003e) received on \u003cstrong\u003eApril 7, 2025\u003c\/strong\u003e. This financing was necessary as cash and cash equivalents stood at \u003cstrong\u003e$32.5 million\u003c\/strong\u003e as of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e. The financing resulted in an immediate dilution of \u003cstrong\u003e22.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. The near-term advantage hinges on successful BLA submission and approval timing. The company recorded a net loss of \u003cstrong\u003e$113.9 million\u003c\/strong\u003e for the year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSupporting Financial and Clinical Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Timeline\u003c\/td\u003e\n\u003ctd\u003eContext\/Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITESSE Topline Results Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4-7 year old BLA support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBLA Submission Target (4-7 Age Group)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAccelerated by \u003cstrong\u003eone year\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITESSE Subject Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e654\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 3 trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Financing Total\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e (€\u003cstrong\u003e284.5 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eTo fund BLA and launch readiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Financing Proceeds (April 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125.5 million\u003c\/strong\u003e (€\u003cstrong\u003e116.3 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eReceived upon closing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmediate Shareholder Dilution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom 2025 financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-financing cash position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePEPITES Responder Rate (Active vs Placebo)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35.3%\u003c\/strong\u003e vs \u003cstrong\u003e13.6%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e12 months, 4-11 year olds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPITOPE ED $\\geq$1,000 mg (36 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eToddlers 1-3 years, OLE study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey Milestones and Financial Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe VITESSE Phase 3 trial is the largest treatment intervention study in peanut allergy, involving \u003cstrong\u003e654\u003c\/strong\u003e subjects.\u003c\/li\u003e\n\u003cli\u003eThe FDA agreement allows for BLA submission without the COMFORT Children study, accelerating the timeline by approximately \u003cstrong\u003eone year\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe 2025 financing secured up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e, with \u003cstrong\u003e$125.5 million\u003c\/strong\u003e received upfront.\u003c\/li\u003e\n\u003cli\u003eNet loss for the year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e was \u003cstrong\u003e$113.9 million\u003c\/strong\u003e, up from \u003cstrong\u003e$72.7 million\u003c\/strong\u003e in 2023.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents increased to \u003cstrong\u003e$69.8 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, following the financing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 3. Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Patents protect the Viaskin® device, the EPIT process, and specific formulations, creating a legal moat around their core product candidates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Most biotechs have IP, but the breadth covering both device and method is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Legal protection makes direct imitation legally risky and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. They must actively defend and maintain this IP, which requires dedicated legal resources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Strong IP provides a long-term shield against direct competition.\u003c\/p\u003e\n\u003cp\u003eSpecifics of the Intellectual Property Portfolio:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Element\u003c\/td\u003e\n\u003ctd\u003ePatent Identifier\/Type\u003c\/td\u003e\n\u003ctd\u003eDate\/Status Reference\u003c\/td\u003e\n\u003ctd\u003eAssignee\/Co-owner\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergen Desensitization Method\u003c\/td\u003e\n\u003ctd\u003ePatent Number: 11931411 (Grant)\u003c\/td\u003e\n\u003ctd\u003eMarch 19, 2024\u003c\/td\u003e\n\u003ctd\u003eDBV Technologies, AP-HP, Université de Paris Cité\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatch Assembly\u003c\/td\u003e\n\u003ctd\u003ePatent Number: D1012296 (Grant)\u003c\/td\u003e\n\u003ctd\u003eJanuary 23, 2024\u003c\/td\u003e\n\u003ctd\u003eDBV Technologies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMethod of Vaccination (Application)\u003c\/td\u003e\n\u003ctd\u003ePublication Number: 20130039958 (Application)\u003c\/td\u003e\n\u003ctd\u003eFebruary 14, 2013 (Publication Date)\u003c\/td\u003e\n\u003ctd\u003eDBV TECHNOLOGIES\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial and Resource Allocation Related to IP and R\u0026amp;D:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch \u0026amp; Development expenses related to Viaskin Peanut in a prior period represented 50% of total R\u0026amp;D expenses (excluding share-based compensation expense).\u003c\/li\u003e\n\u003cli\u003eOperating expenses for the nine months ended September 30, 2024, included costs associated with trademark and patent activities.\u003c\/li\u003e\n\u003cli\u003eCash used in operations for the nine months ended September 30, 2023, totaled $79.6 million, primarily in Research and Development.\u003c\/li\u003e\n\u003cli\u003eNet cash flows from financing activities for the nine months ended September 30, 2025, were $117.1 million.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of December 31, 2023, were $141.4 million.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were $69.8 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 4. Recent Liquidity and Capital Access\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe financing announced on March 27, 2025, secured up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e (\u003cstrong\u003e€284.5 million\u003c\/strong\u003e). The initial tranche received gross proceeds of \u003cstrong\u003e$125.5 million\u003c\/strong\u003e (\u003cstrong\u003e€116.3 million\u003c\/strong\u003e) on April 7, 2025. Cash and cash equivalents stood at \u003cstrong\u003e$103.2 million\u003c\/strong\u003e as of June 30, 2025, with the Company estimating this was sufficient to fund operations into the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Secured (Maximum)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$306.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 27, 2025 Announcement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Proceeds Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$125.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApril 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$103.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$69.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Financing Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$117.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSecuring a financing of up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e in the reported period represents a significant, though temporary, access to capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe ability to execute capital raises is generally accessible to public companies, though the specific timing and market conditions impacting the valuation are not controllable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe establishment of the At-The-Market (ATM) Program on \u003cstrong\u003eSeptember 5, 2025\u003c\/strong\u003e, demonstrates a proactive organizational structure for accessing capital.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eATM Program established on \u003cstrong\u003eSeptember 5, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSale of approximately \u003cstrong\u003e$30 million\u003c\/strong\u003e of ADSs announced on \u003cstrong\u003eOctober 6, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe October sale involved issuing \u003cstrong\u003e11,538,460 new Ordinary Shares\u003c\/strong\u003e underlying \u003cstrong\u003e2,307,692 ADSs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe issuance price was \u003cstrong\u003e$13.00 per ADS\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe ATM issuance limit is less than \u003cstrong\u003e30%\u003c\/strong\u003e of ordinary shares over a rolling \u003cstrong\u003e12 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe October ATM sale is projected to extend the financial runway to the end of the \u003cstrong\u003efourth quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined capital access provides a cash buffer extending operational funding visibility into the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e, with the subsequent ATM program extending this to the end of the \u003cstrong\u003efourth quarter of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 5. Regulatory Expertise and Dual-Market Strategy\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Experience navigating both the FDA (US) and AMF (France) processes, crucial for a company with European roots targeting the massive US market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Experience with both major regulatory bodies in this specific therapeutic area is not common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can hire experts, but the institutional memory from past interactions is hard to copy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are clearly structured to manage dual filings, evidenced by their regular 10-Q and URD filings.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep, proven regulatory experience reduces execution risk on BLA submissions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory Body\/Filing\u003c\/th\u003e\n\u003cth\u003eProduct Indication\u003c\/th\u003e\n\u003cth\u003eKey Target\/Outcome\u003c\/th\u003e\n\u003cth\u003eAssociated Date\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA (US)\u003c\/td\u003e\n\u003ctd\u003eViaskin Peanut (4–7-year-olds)\u003c\/td\u003e\n\u003ctd\u003eBLA Submission Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1H 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA (US)\u003c\/td\u003e\n\u003ctd\u003eViaskin Peanut (1–3-year-olds)\u003c\/td\u003e\n\u003ctd\u003eBLA Submission Target (Accelerated Approval)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2H 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA (US)\u003c\/td\u003e\n\u003ctd\u003eVITESSE Phase 3 Study\u003c\/td\u003e\n\u003ctd\u003eTopline Results Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA (US)\u003c\/td\u003e\n\u003ctd\u003eCOMFORT Toddlers Study\u003c\/td\u003e\n\u003ctd\u003eStudy Initiation Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2Q 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC \/ AMF\u003c\/td\u003e\n\u003ctd\u003eAnnual Reporting\u003c\/td\u003e\n\u003ctd\u003eFiling of Form 10-K (US GAAP) and URD (AMF\/IFRS)\u003c\/td\u003e\n\u003ctd\u003eMarch 8, 2024 (for FY 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organizational capacity to manage these parallel regulatory tracks is supported by key personnel appointments and financial management:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAppointment of Robert Pietrusko, PharmD, as Chief Regulatory Officer, bringing over \u003cstrong\u003efour decades\u003c\/strong\u003e of biopharmaceutical regulatory experience.\u003c\/li\u003e\n\u003cli\u003eThe successful navigation of FDA feedback, leading to an agreement that potentially accelerates the 4–7-year-old BLA timeline by approximately \u003cstrong\u003eone year\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's financial structure reflects the high cost of this dual-market regulatory execution: Cash and cash equivalents were \u003cstrong\u003e$32.5 million\u003c\/strong\u003e as of December 31, 2024, following a net cash consumption of \u003cstrong\u003e$108.9 million\u003c\/strong\u003e during 2024.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents stood at \u003cstrong\u003e$101.5 million\u003c\/strong\u003e as of March 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 6. Commercial Strategy Leadership\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The appointment of Kevin Trapp as Chief Commercial Officer, effective November 3, 2025, signals a concrete shift from clinical focus to market readiness for Viaskin® Peanut. Mr. Trapp will lead all aspects of global commercial strategy and execution for the patch. This move is supported by financing secured in March 2025, up to \u003cstrong\u003e$306.9 million\u003c\/strong\u003e (€284.5 million), intended to advance the program through BLA submission and U.S. commercial launch, if approved.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Experienced CCOs with deep biopharma commercialization history are scarce resources. Mr. Trapp brings over \u003cstrong\u003e30 years\u003c\/strong\u003e of experience in the biopharmaceutical industry, including prior roles at Bristol-Myers Squibb.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Recruiting top-tier commercial talent is difficult and time-consuming for competitors. The successful recruitment of a seasoned leader like Mr. Trapp, who previously consulted for DBV since 2017, is a high barrier for rivals attempting to quickly build equivalent commercial leadership.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Placing a seasoned leader directly under the CEO, Daniel Tasse, to lead global commercial strategy shows clear organizational alignment. This structure is designed to execute on the anticipated Biologics License Application (BLA) submission for children aged 4-7 years in the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage is only sustained if Mr. Trapp successfully builds out the commercial infrastructure effectively to capture a share of the Peanut Allergy Treatment Market, valued at approximately \u003cstrong\u003eUSD 533 million\u003c\/strong\u003e in the 7MM in 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$69.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $32.5 million at December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Annual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA decrease of \u003cstrong\u003e73.61%\u003c\/strong\u003e year-over-year from 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (9 months ended Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $90.9 million for the same period in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Peanut Allergy Market Size (2034)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 2,464 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProjected CAGR of \u003cstrong\u003e18.50%\u003c\/strong\u003e from 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViaskin Peanut BLA Submission (4-7 yr olds)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated submission following VITESSE Phase 3 results in Q4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey Commercial and Regulatory Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eViaskin Peanut VITESSE Phase 3 topline results anticipated in the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated Biologics License Application (BLA) submission for children 4-7 years-old in the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated BLA submission for children 1-3 year-olds in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for the nine months ended September 30, 2025, were \u003cstrong\u003e$107.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash flows used in operating activities were \u003cstrong\u003e$86.0 million\u003c\/strong\u003e for the nine months ended September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 7. Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated ability to run complex, multi-site trials like VITESSE, enrolling specific populations like toddlers (1-3 years) and children (4-7 years).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVITESSE Phase 3 pivotal study enrolled 654 subjects (randomized 2:1) across 86 participating sites in US, Canada, Europe, UK, and Australia.\u003c\/li\u003e\n\u003cli\u003eCompleted EPITOPE Phase 3 trial in toddlers (1 – 3-year-olds) which enrolled 362 children.\u003c\/li\u003e\n\u003cli\u003eEPITOPE: 67% of the treatment arm met response criteria at 12 months versus 33.5% in the control group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Running successful pediatric trials in this space requires specialized site relationships.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVITESSE is currently the largest treatment intervention study in peanut allergy.\u003c\/li\u003e\n\u003cli\u003eThe COMFORT Toddlers supplemental safety study plans to enroll approximately 480 subjects at approximately 80 – 90 study centers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building the necessary network of specialized clinical sites takes years.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 86 sites for VITESSE span five major geographical regions (US, Canada, Europe, UK, Australia).\u003c\/li\u003e\n\u003cli\u003eThe global clinical trial investigative site network market size was $8.83 billion in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Continued progress in enrollment and study management shows operational discipline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses for the six months ended June 30, 2024, amounted to $65.0 million, driven by R\u0026amp;D including patient enrollment in VITESSE.\u003c\/li\u003e\n\u003cli\u003eCash balance was $66.2 million as of June 30, 2024.\u003c\/li\u003e\n\u003cli\u003eTopline results for VITESSE are expected by Q4 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The established network of clinical sites and trial management expertise is a valuable operational asset.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITESSE Enrolled Subjects\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e654\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITESSE Participating Sites\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPITOPE Toddler Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e362\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPITOPE Toddler Treatment Response (12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected VITESSE Topline Data\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 8. Dual Stock Exchange Listing (Euronext Paris \u0026amp; NASDAQ)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAccess to two distinct pools of capital - European and US - diversifying funding sources.\u003c\/li\u003e\n\u003cli\u003eRecent capital event: Agreed to sell approximately \u003cstrong\u003e$30 million\u003c\/strong\u003e of ADSs through its At-The-Market program on Nasdaq in October 2025.\u003c\/li\u003e\n\u003cli\u003eNew ATM Program established in September 2025 for up to \u003cstrong\u003e$150M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMany European biotechs list on NASDAQ.\u003c\/li\u003e\n\u003cli\u003eMaintaining dual listing compliance is a specific capability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe cost and compliance burden deter many smaller firms from maintaining this structure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActive use of the NASDAQ ATM program to tap US equity markets efficiently.\u003c\/li\u003e\n\u003cli\u003eOctober 2025 ATM Issuance: 10,714,300 new Ordinary Shares underlying 2,142,860 new ADSs issued.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSustained structural flexibility in capital raising.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eEuronext Paris Listing (DBV)\u003c\/th\u003e\n\u003cth\u003eNASDAQ Listing (DBVT)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTicker Symbol\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDBV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDBVT\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Market Capitalization Reference\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€407.8m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.55 Billion USD\u003c\/strong\u003e (December 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Share Price Reference (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€2.274\u003c\/strong\u003e (December 07, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$13.00\u003c\/strong\u003e per ADS (October 2025 ATM price)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Capital Raise Mechanism\u003c\/td\u003e\n\u003ctd\u003eNew Ordinary Shares admitted to trading\u003c\/td\u003e\n\u003ctd\u003eAt-The-Market (ATM) Program for ADSs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Recent ATM (Oct 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Impacted by transaction)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDilution from Recent ATM\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e7.77%\u003c\/strong\u003e dilution to existing shares\u003c\/td\u003e\n\u003ctd\u003eRepresents \u003cstrong\u003e8.42%\u003c\/strong\u003e of existing shares already admitted to trading on Euronext Paris\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDBV Technologies S.A. (DBVT) - VRIO Analysis: 9. Focused Therapeutic Area Expertise (Food Allergies)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, singular focus on food allergies and immunologic conditions with unmet need, allowing for concentrated R\u0026amp;D spend and specialized scientific knowledge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many biotechs focus on immunology, DBV Technologies has concentrated its entire effort on this niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Shifting a company's entire focus and scientific base is a massive undertaking for a competitor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. All resources, from R\u0026amp;D to commercial planning, are aligned toward solving food allergy treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Concentrated expertise builds a deeper moat than broad, unfocused research efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMarket Potential:\u003c\/strong\u003e Projected peak sales exceeding $2 billion for Viaskin Peanut.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct Pipeline Focus:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eViaskin Peanut: Immunotherapy for peanut allergies.\u003c\/li\u003e\n\u003cli\u003eViaskin Milk: Treatment for cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis.\u003c\/li\u003e\n\u003cli\u003eViaskin Egg: Development program for hen's egg allergy.\u003c\/li\u003e\n\u003cli\u003eDiallertest Milk: Diagnostic product for CMPA in children.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial Metrics (Nine Months Ended September 30, 2025):\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (USD Millions)\u003c\/td\u003e\n\u003ctd\u003e9M Ended Sep 30, 2025\u003c\/td\u003e\n\u003ctd\u003e9M Ended Sep 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e46.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Flow Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(86.0)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(92.2)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(83.8)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(70.4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e107.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e96.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(102.1)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(90.9)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRecent Financing Activity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFinancing announced March 27, 2025, up to $306.9 million (€284.5 million).\u003c\/li\u003e\n\u003cli\u003eGross proceeds received upon closing: $125.5 million (€116.3 million) on April 7, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cp\u003eFinance: draft the Q4 2025 cash burn projection, factoring in the October $30 million raise, by Friday.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ4 2025 Cash Burn Projection Note:\u003c\/strong\u003e Factoring in the October $30 million raise and the average monthly operating cash burn of approximately $9.56 million (based on $86.0 million used over the nine months ended September 30, 2025), the projected cash position at the end of Q4 2025 would be approximately $71.12 million ($69.8M cash at Q3 end + $30M raise - ($9.56M\/month  3 months)).\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516149358741,"sku":"dbvt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dbvt-vrio-analysis.png?v=1740166043","url":"https:\/\/dcf-model.com\/es\/products\/dbvt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}